Search our Database of Scientific Publications and Authors

I’m looking for a

    Details and Download Full Text PDF:
    Update on the management of venous thromboembolism.

    Cleve Clin J Med 2017 Dec;84(12 Suppl 3):39-46
    Section Head, Department of Vascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA.
    Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism, is a common cardiovascular disease associated with significant morbidity ranging from painful leg swelling, chest pain, shortness of breath, and even death. Long-term complications include recurrent VTE, postpulmonary embolism syndrome, chronic thromboembolic pulmonary hypertension, and postthrombotic syndrome (PTS). Management of VTE requires immediate anticoagulation therapy based on a risk assessment for bleeding. Direct oral anticoagulants (DOACs) have become an important option for patients as reflected in the most recent American College of Chest Physician treatment guidelines.
    PDF Download - Full Text Link
    ( Please be advised that this article is hosted on an external website not affiliated with
    Source Status ListingPossible

    Similar Publications

    Management of venous thromboembolism: an update.
    Thromb J 2016 4;14(Suppl 1):23. Epub 2016 Oct 4.
    Department of Medicine, Division of Hematology and Thromboembolism, and Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON L8L 2X2 Canada.
    Venous thromboembolism (VTE), which constitutes pulmonary embolism and deep vein thrombosis, is a common disorder associated with significant morbidity and mortality. Landmark trials have shown that direct oral anticoagulants (DOACs) are as effective as conventional anticoagulation with vitamin K antagonists (VKA) in prevention of VTE recurrence and associated with less bleeding. This has paved the way for the recently published guidelines to change their recommendations in favor of DOACs in acute and long-term treatment of VTE in patients without cancer. Read More
    Thrombolysis for acute deep vein thrombosis.
    Cochrane Database Syst Rev 2016 11 10;11:CD002783. Epub 2016 Nov 10.
    Cameron House, Cameron Bridge, Windygates, Leven, UK, KY8 5RG.
    Background: Standard treatment for deep vein thrombosis aims to reduce immediate complications. Use of thrombolysis or clot dissolving drugs could reduce the long-term complications of post-thrombotic syndrome (PTS) including pain, swelling, skin discolouration, or venous ulceration in the affected leg. This is the third update of a review first published in 2004. Read More
    Guidance for the treatment of deep vein thrombosis and pulmonary embolism.
    J Thromb Thrombolysis 2016 Jan;41(1):32-67
    Department of Medicine, Hofstra North Shore/LIJ School of Medicine, Hempstead, NY, USA.
    This guidance document focuses on the diagnosis and treatment of venous thromboembolism (VTE). Efficient, cost effective diagnosis of VTE is facilitated by combining medical history and physical examination with pre-test probability models, D dimer testing and selective use of confirmatory imaging. Clinical prediction rules, biomarkers and imaging can be used to tailor therapy to disease severity. Read More
    Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
    Thromb Res 2015 Feb 2;135(2):243-8. Epub 2014 Dec 2.
    Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
    Introduction: The duration of anticoagulation after venous thromboembolic events (VTE) is based on the balance between the risk of recurrent VTE and bleeding. The purpose of this study was to estimate the frequency and case-fatality rate of major bleeding and recurrent VTE during secondary prevention of VTE.

    Materials And Methods: MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials databases were searched through September 2014. Read More